Testosterone Gel for Women with Low Testosterone and Symptoms

Direct Answer

Transdermal testosterone gel can be prescribed off-label for postmenopausal women with documented low serum testosterone and hypoactive sexual desire disorder (HSDD), but no FDA-approved testosterone formulation exists for women, requiring careful use of male-formulated products at much lower doses. 1, 2, 3

Indications and Expected Benefits

Primary Indication

The primary evidence-based indication is hypoactive sexual desire disorder (HSDD) in postmenopausal women who have persistent, distressing loss of sexual desire that causes personal distress. 2, 3
Testosterone therapy significantly improves sexual function, desire, arousal, frequency of satisfying sexual episodes, and overall sexual satisfaction compared to placebo or estrogen alone. 2, 3, 4

Secondary Symptoms

Persistent unexplainable fatigue or lack of energy may improve with testosterone therapy. 5, 3
Decreased sense of personal well-being and blunted motivation are associated with androgen deficiency and may respond to treatment. 5, 3
Testosterone therapy provides little to no benefit for general mood, depression, or physical functioning as primary complaints. 6

Diagnostic Confirmation Required

Biochemical Testing

Measure morning total testosterone (8-10 AM) on two separate occasions to confirm low levels, though no standardized female threshold exists. 6, 5
Measure free testosterone by equilibrium dialysis or calculate using validated formulas (not direct immunoassay), as this is the biologically active fraction. 6, 5
Measure sex hormone-binding globulin (SHBG), as oral estrogen therapy increases SHBG and reduces free testosterone. 5, 3
Low bioavailable testosterone is defined as total testosterone/SHBG ratio in the lower one-third of the female reproductive range. 5

Clinical Criteria

Both biochemical evidence of low testosterone AND specific symptoms (primarily HSDD) must be present before initiating therapy. 6, 5, 3
Symptoms alone without biochemical confirmation are insufficient to justify treatment. 6

Dosing and Administration

Recommended Regimen

Start with 5 mg transdermal testosterone gel or cream applied daily or less, as this is the suggested trial dose for women. 2
Male-formulated testosterone gel 1.62% must be used off-label, as no female-specific formulation is FDA-approved in the United States or Europe. 1, 2
For reference, one pump actuation of male testosterone gel 1.62% delivers 20.25 mg—approximately 4 times the recommended female starting dose. 1

Application Instructions

Apply to clean, dry, intact skin once daily, preferably in the morning. 1
For women, apply to the lower abdomen or inner thigh (not upper arms/shoulders as directed for men), using approximately one-quarter of a single pump actuation or less. 1, 2
Allow gel to dry completely before covering with clothing. 1
Wash hands thoroughly with soap and water immediately after application. 1
Avoid swimming or washing the application site for at least 2 hours after application. 1

Baseline and Follow-Up Laboratory Monitoring

Pre-Treatment Labs

Morning total testosterone (8-10 AM) on two occasions 6, 5
Free testosterone by equilibrium dialysis or calculated 6, 5
Sex hormone-binding globulin (SHBG) 5, 3
Baseline hematocrit or hemoglobin 6
Baseline lipid profile 7
Liver function tests (AST, ALT) 4

Follow-Up Monitoring

Measure total and free testosterone at 4-6 weeks after initiation, then every 3-6 months for the first year. 6, 1, 2
Target testosterone levels at the upper portion or slightly above the reference range for reproductive-aged women. 7
Monitor hematocrit every 6-12 months, as testosterone can increase red blood cell production. 6, 4
Monitor lipid profile every 6-12 months, particularly with oral testosterone (transdermal has minimal lipid effects). 7, 4
Monitor liver enzymes every 6-12 months. 4
Reassess clinical symptoms, particularly sexual function, at 8-12 weeks and every 6 months thereafter. 2, 4

Monitoring for Virilization and Adverse Effects

Signs of Virilization to Monitor

Acne or oily skin (most common, mild, and reversible) 2, 7, 4
Hirsutism (increased facial or body hair, mild and reversible) 2, 7
Voice deepening (rare at low doses, potentially irreversible) 2
Clitoral enlargement (rare at low doses) 1
Male-pattern hair loss (rare at low doses) 2

Management of Virilization

If mild virilization occurs (acne, mild hirsutism), reduce dose by 50% and reassess in 4-6 weeks. 2, 7
If moderate to severe virilization occurs (voice changes, clitoral enlargement), discontinue testosterone immediately. 1, 2
Most virilization effects are reversible with dose reduction or discontinuation, except voice deepening. 2, 7

Other Adverse Effects

No increased risk of endometrial hyperplasia has been demonstrated in short-term studies (up to 2 years). 7, 4
No adverse cardiovascular effects, including changes in blood pressure, blood viscosity, or hypercoagulable states, have been shown with transdermal testosterone. 7
Oral testosterone (not transdermal) can adversely affect lipid profiles, increasing LDL and decreasing HDL. 7
No hepatotoxicity has been demonstrated with transdermal testosterone at physiologic doses. 7

Absolute Contraindications

Pregnancy or women attempting to conceive (testosterone causes virilization of female fetus) 1
Known or suspected breast cancer (theoretical risk, though some data suggest protective effects) 1, 7
Active liver disease or significantly elevated liver enzymes 7
Polycythemia or hematocrit >48% 6
Untreated cardiovascular disease or recent cardiovascular event within 3-6 months 6, 8

Relative Contraindications and Precautions

Oral estrogen therapy increases SHBG and reduces free testosterone, potentially requiring higher testosterone doses or switching to transdermal estrogen. 5, 3
Women with polycystic ovarian syndrome (PCOS) already have elevated androgens and should not receive testosterone therapy. 7
Testosterone therapy should be used with caution in women with cardiovascular risk factors, targeting mid-range testosterone levels. 6, 7

Alternative and Adjunctive Treatments

First-Line Non-Hormonal Approaches

Address underlying causes of low libido first: relationship issues, depression, anxiety, medications (SSRIs, antihypertensives), sleep disorders, chronic illness. 6, 3
Optimize estrogen therapy for postmenopausal women, as adequate estrogen is required for testosterone to be effective. 5, 3
Switch from oral to transdermal estrogen if SHBG is elevated, as oral estrogen significantly increases SHBG and reduces free testosterone. 5, 3

Hormonal Alternatives

Estrogen therapy alone improves vaginal symptoms but has no effect on sexual desire, making it insufficient for HSDD. 2
Combination estrogen plus testosterone is more effective than estrogen alone for improving sexual function. 3, 4
No selective estrogen receptor modulators (SERMs) or other hormonal alternatives have proven efficacy for female HSDD. 6

Lifestyle Modifications

Weight loss and regular exercise can improve endogenous testosterone production in obese women with secondary hypogonadism. 6, 9
Smoking cessation and reducing alcohol intake may improve sexual function. 6

Critical Pitfalls to Avoid

Never prescribe testosterone without confirming both low testosterone levels AND specific symptoms (primarily HSDD). 6, 5, 3
Never use male-formulated testosterone gel at male doses in women—this will cause rapid virilization. 1, 2
Never prescribe testosterone to women who are pregnant, attempting to conceive, or not using reliable contraception (if premenopausal). 1
Never ignore signs of virilization—dose reduction or discontinuation is required immediately. 1, 2
Never prescribe testosterone for general fatigue, mood, or physical functioning as primary complaints without documented HSDD. 6, 3
Never use oral methyltestosterone as first-line therapy—transdermal preparations have superior safety profiles. 5, 7
Never prescribe testosterone without adequate estrogen replacement in postmenopausal women, as estrogen is required for testosterone efficacy. 5, 3
Never assume that higher testosterone levels will produce better results—target physiologic female levels, not supraphysiologic levels. 7

Duration of Therapy and Discontinuation

Reassess clinical response at 8-12 weeks—if no improvement in sexual function, discontinue therapy. 6, 2, 4
Short-term studies up to 2 years have demonstrated safety, but long-term safety data beyond 2 years are lacking. 3, 7
Discontinue testosterone if virilization occurs, if no clinical benefit is observed after 3-6 months, or if contraindications develop. 1, 2, 7

Special Populations

Surgically Menopausal Women (Bilateral Oophorectomy)

Surgically menopausal women are the population most likely to benefit from testosterone therapy, as testosterone levels decline by approximately 50% after oophorectomy. 5, 3
These women often have the most severe androgen deficiency symptoms. 5

Premenopausal Women with Premature Ovarian Failure

Testosterone replacement may be considered as an adjunct to estrogen therapy in women with premature ovarian failure and HSDD. 5
Ensure reliable contraception, as testosterone is teratogenic. 1

Women on Oral Estrogen Therapy

Oral estrogen significantly increases SHBG, reducing free testosterone and potentially worsening androgen deficiency symptoms. 5, 3
Consider switching to transdermal estrogen before initiating testosterone therapy. 5, 3

Help us tailor your experience